Posts by Sabashini Ramchand, MBBS
-
After Denosumab Discontinuation, Alendronate Superior to Raloxifene at Maintaining BMD Gains
Massachusetts General Hospital researchers found that for postmenopausal women with osteoporosis who discontinue short-term denosumab treatment and are unable or unwilling to transition to a bisphosphonate, raloxifene may be a suitable alternative, although inferior in maintaining the gain in bone mineral density.
-
A Dose of Zoledronate Maintains Bone Mineral Density in Osteoporosis
According to a recent study, a single dose of zoledronate maintains the increases in the femoral neck and total hip bone mineral density achieved with combination teriparatide/denosumab for at least 27 months.
Rheumatology, Allergy and Immunology
The Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital provides leading-edge treatment and transformative care to patients with rheumatic disease and autoimmune conditions.